Improves blood glucose control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the recommended dose of this medicine is determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: empagliflozin 25 mg, sitagliptin 100 mg, and extended-release metformin hydrochloride 2000 mg.
To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with a meal in the evening, with gradual dose titration.
Patients taking this medicine as 25/100/1000 mg or 10/100/1000 mg extended-release tablets should take 1 tablet once daily.
Patients taking this medicine as 12.5/50/750 mg or 5/50/750 mg extended-release tablets should take 2 tablets together once daily.
For patients whose blood glucose is not adequately controlled with metformin and sitagliptin, the starting dose of this medicine should be empagliflozin 10 mg, sitagliptin 100 mg, and the metformin hydrochloride dose the patient was taking, or an appropriate dose therapeutically equivalent to it. If empagliflozin 10 mg is tolerated and additional glycemic control is needed, the dose of empagliflozin may be increased to 25 mg.
For patients switching from combination therapy with empagliflozin, sitagliptin, and metformin to this medicine, use the dose of each component that the patient was previously taking.
The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other antihyperglycemic agents. Since such a change may result in changes in glycemic control, any change in treatment for patients with type 2 diabetes should be made under careful monitoring.
To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. This medicine may not dissolve completely and may be excreted in the stool.
It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If the patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions).
No dose adjustment is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73
m2].
In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis.
The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg.
If creatinine clearance (CrCl) decreases to less than 45 mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, this medicine should be discontinued immediately.
Improves blood glucose control in adults with type 2 diabetes mellitus
View approved original textHide original text
This medication is used in adult patients with type 2 diabetes to improve blood sugar control, complementing dietary and exercise regimens. The three components—empagliflozin, sitagliptin, and metformin—work together to effectively lower blood sugar levels. Therefore, this medication plays a significant role in the management of diabetes for patients.
How to take
Adult dose
For antidiabetic therapy, the recommended dose of this medicine is determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: empagliflozin 25 mg, sitagliptin 100 mg, and extended-release metformin hydrochloride 2000 mg.
To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with a meal in the evening, with gradual dose titration.
Patients taking this medicine as 25/100/1000 mg or 10/100/1000 mg extended-release tablets should take 1 tablet once daily.
Patients taking this medicine as 12.5/50/750 mg or 5/50/750 mg extended-release tablets should take 2 tablets together once daily.
For patients whose blood glucose is not adequately controlled with metformin and sitagliptin, the starting dose of this medicine should be empagliflozin 10 mg, sitagliptin 100 mg, and the metformin hydrochloride dose the patient was taking, or an appropriate dose therapeutically equivalent to it. If empagliflozin 10 mg is tolerated and additional glycemic control is needed, the dose of empagliflozin may be increased to 25 mg.
For patients switching from combination therapy with empagliflozin, sitagliptin, and metformin to this medicine, use the dose of each component that the patient was previously taking.
The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other antihyperglycemic agents. Since such a change may result in changes in glycemic control, any change in treatment for patients with type 2 diabetes should be made under careful monitoring.
To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. This medicine may not dissolve completely and may be excreted in the stool.
It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If the patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions).
No dose adjustment is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73
m2].
In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis.
The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg.
If creatinine clearance (CrCl) decreases to less than 45 mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, this medicine should be discontinued immediately.
Precautions
This medication may rarely cause serious allergic reactions due to the sitagliptin component. If any symptoms such as skin rash, difficulty in breathing, or swelling of the face or neck occur after taking the medication, it should be stopped immediately, and a doctor should be consulted.
Additionally, sitagliptin may cause acute pancreatitis; hence, if symptoms like abdominal pain, vomiting, or persistent nausea develop after use, medical attention should be sought immediately.
Although rare, metformin can cause a severe metabolic disorder known as lactic acidosis. Therefore, patients with impaired renal function, severe infections, dehydration, or heart failure should not use this medication.
This medication should not be administered to patients with type 1 diabetes, acute metabolic acidosis, or moderate to severe renal impairment.
If scheduled for surgery or in states of severe infection or trauma, it is advisable to temporarily discontinue this medication and resume after stabilization.
Patients with decreased kidney function should undergo regular kidney function tests, and the medication should not be taken if kidney function is significantly compromised.
This medication carries a risk of hypoglycemia; therefore, especially when taken with other hypoglycemic agents, blood glucose levels should be monitored regularly, and symptoms of hypoglycemia should be observed closely.
Moreover, this medication may increase the risk of genital and urinary tract infections; prompt treatment should be sought if symptoms of infection occur.
Fluid loss or dehydration can occur; thus, in cases of vomiting or diarrhea that impede fluid intake, it is advisable to temporarily stop the medication and consult a doctor.
It is safe for pregnant women or those with placental insufficiency to avoid using this medication.
Regular blood tests and health status monitoring are needed during the course of this medication, and any abnormal symptoms should be reported to healthcare professionals immediately.
Side effects
Hypersensitivity
anaphylaxis
angioedema
Stevens-Johnson syndrome
exfoliative skin disease
acute pancreatitis
lactic acidosis
influenza
nasopharyngitis
perianal abscess
Show 156 moreCollapse
perforated appendicitis
cervicitis
coronavirus infection
otitis media
periodontitis
tooth abscess
vaginal infection
dyspepsia
abdominal pain
upper abdominal pain
diarrhea
dry mouth
alcoholic gastritis
erosive gastritis
hematemesis
hemorrhoids
nausea
chest pain
weakness
fatigue
increased blood glucose
weight loss
increased serum creatine phosphokinase
eyelid twitching
diabetic retinopathy
keratitis
vitreous hemorrhage
bladder transitional cell carcinoma
prostate cancer
renal cell carcinoma
right atrial block
left ventricular hypertrophy
hyperglycemia
hypoglycemia
vulvar pruritus
diaphoresis
dermatitis
bile duct obstruction
forearm fracture
headache
insomnia
frequent urination
sleep apnea syndrome
removal of artificial fixtures
vomiting
change in bowel habits
colitis
dental caries
gastroenteritis
external auditory canal inflammation
cataract
borderline glaucoma
endocrine ophthalmopathy
arthralgia
lumbar spinal stenosis
spinal canal stenosis
cough
eosinophilic bronchitis
oropharyngeal pain
contusion
foot fracture
radiculopathy
thalamic infarction
breast mass
keloid scar
rash
aortic aneurysm
hypotension
ventricular ectopic contraction
gill pouch
vomiting
upper abdominal pain
gastric ulcer
ischemic colitis
colonic bleeding
soft tissue infection
appendiceal abscess
meningitis
chronic otitis media
peritonsillar abscess
pneumonia
pulmonary tuberculosis
acute pyelonephritis
sepsis
subcutaneous abscess
tubo-ovarian abscess
vestibular neuritis
acute pyelonephritis
headache
cerebral infarction
intracranial aneurysm
fever
vascular stent stenosis
vascular stent thrombosis
increased alanine aminotransferase
increased aspartate aminotransferase
ureterolithiasis
acute kidney injury
cervicitis
hyperglycemia
hyponatremia
diabetic foot
back pain
glaucoma
pathological myopia
retinal detachment
retinal vein occlusion
rhegmatogenous retinal detachment
limb injury
traffic accident
splenic injury
sternum fracture
angina
Prinzmetal angina
coronary artery disease
deep vein thrombosis
acute cholecystitis
autoimmune hepatitis
cholelithiasis
unstable angina
anxiety
depression
sleep disorders
acute cholecystitis
hepatitis
otalgia
positional vertigo
dizziness
chest discomfort
chest pain
weakness
weight loss
vulvar pruritus
genital pruritus
dyslipidemia
hyperglycemia
lumbar spinal stenosis
back pain
diabetic retinopathy
dry eyes
cough
dyspnea
unstable angina
hypertension
hypoglycemia
urticaria
angioedema
thrombocytopenia
rhabdomyolysis
severe and disabling arthralgia
vesicular pemphigoid
myalgia
limb pain
back pain
interstitial lung disease
pruritus
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a tightly sealed container to protect it from air and moisture. It is recommended to keep it at room temperature between 1 to 30 degrees Celsius.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.